

PROSAAS Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP54595

Product Information

Application Primary Accession Reactivity Host Clonality Calculated MW Physical State Immunogen Epitope Specificity Isotype Purity	IHC-P, IHC-F, IF, ICC, E Q9UHG2 Human Rabbit Polyclonal 27372 Liquid KLH conjugated synthetic peptide derived from human PROSAAS 34-130/260 IgG affinity purified by Protein A
Buffer SUBCELLULAR LOCATION SUBUNIT Post-translational modifications	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Secreted. Golgi apparatus > trans-Golgi network. A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis-parkinsonism/dementia complex 1. Interacts via the C-terminal inhibitory domain with PCSK1 65 kDa form. Proteolytically cleaved in the Golgi. Big SAAS, Little SAAS, PEN and Big LEN are the major processed peptides in proSAAS-overexpressing PC-12
Important Note Background Descriptions	phaeochromocytoma cells (lacking PCSK1 and PCSK2 endopeptidases). Peptides corresponding to PEN and a proSAAS aa 40-59 have been detected in wild-type PC-12 cells. This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. The protein encoded by this gene functions as an inhibitor of prohormone convertase 1, which regulates the proteolytic cleavage of neuroendocrine
	peptide precursors. The proprotein is further processed into multiple short peptides. A polymorphism within this gene may be associated with obesity. [provided by RefSeq, Aug 2013]

Additional Information

Gene ID	27344
Other Names	ProSAAS, Proprotein convertase subtilisin/kexin type 1 inhibitor, Proprotein convertase 1 inhibitor, pro-SAAS, KEP, Big SAAS, b-SAAS, Little SAAS, I-SAAS, N-proSAAS, Big PEN-LEN, b-PEN-LEN, SAAS CT(1-49), PEN, Little LEN, I-LEN, Big LEN, b-LEN, SAAS CT(25-40), PCSK1N
Target/Specificity	Expressed in brain and pancreas.

Dilution	IHC-P=1:100-500,IHC-F=1:100-500,ICC=1:100-500,IF=1:100-500,ELISA=1:5000- 10000
Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information	
Name	PCSK1N
Function	May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity (By similarity).
Cellular Location	Secreted {ECO:0000250 UniProtKB:Q9QXV0}. Golgi apparatus, trans-Golgi network {ECO:0000250 UniProtKB:Q9QXV0}. Note=A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis- parkinsonism/dementia complex 1 (Guam disease)
Tissue Location	Expressed in brain and pancreas.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.